Joseph Lozito, DO
Family Medicine · Hawthorne, NJNPI 1821120692
Payments from drug & device makers
Across 176 payments — averaging $30.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$3K
- Novo Nordisk$619
- Merck$194
- Pfizer$193
- AbbVie$189
- Boehringer Ingelheim$174
- plus $999 from 24 others
What the payments were for
- Consulting fees$2,62049%
- Food & beverage$2,69451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 22 | $2,947 |
| Novo Nordisk | 43 | $619 |
| Merck | 14 | $194 |
| Pfizer | 12 | $193 |
| AbbVie(2 entities) | 11 | $189 |
| Boehringer Ingelheim | 10 | $174 |
| AstraZeneca | 10 | $142 |
| GSK | 6 | $88 |
| Exact Sciences | 3 | $82 |
| Lilly USA, LLC | 5 | $73 |
| Amarin Pharma, Inc. | 4 | $57 |
| Genentech USA, Inc. | 4 | $57 |
| Myovant Sciences Inc. | 3 | $54 |
| Novartis | 3 | $45 |
| Topcon Healthcare Solutions, Inc. | 1 | $42 |
| Amgen | 3 | $42 |
| Arbor Pharmaceuticals, Inc. | 3 | $40 |
| Abbott | 2 | $35 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| Sanofi Pasteur Inc. | 2 | $29 |
| Almatica Pharma LLC | 2 | $29 |
| Lupin Inc. | 2 | $27 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| VBI Vaccine (delaware) Inc. | 1 | $15 |
| Gilead | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Shire North American Group Inc | 1 | $13 |
How this compares
$5,314 in reported general payments places this provider in the 85th percentile of 2,084 family medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 139 | $106,399 |
| OzempicSemaglutide | 46 | $44,682 |
| RybelsusSemaglutide | 40 | $43,283 |
| JanuviaSitagliptin Phosphate | 36 | $36,925 |
| TrulicityDulaglutide | 28 | $26,580 |
| JardianceEmpagliflozin | 21 | $20,263 |
| XareltoRivaroxaban | 16 | $18,119 |
| Tresiba Flextouch U-100Insulin Degludec | 28 | $16,265 |
| MyrbetriqMirabegron | 24 | $11,125 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $9,572 |
| NeuproRotigotine | 12 | $9,466 |
| Spiriva RespimatTiotropium Bromide | 14 | $8,470 |
| SymbicortBudesonide/Formoterol Fumarate | 28 | $8,320 |
| Colesevelam Hcl | 19 | $8,173 |
| RestasisCyclosporine | 16 | $7,004 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $193 | $106,399139 claims |
| Novo NordiskOzempic, Rybelsus | $619 | $87,96686 claims |
| MerckJanuvia | $194 | $36,92536 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $174 | $28,73335 claims |
| Lilly USA, LLCTrulicity | $73 | $26,58028 claims |
| Johnson & JohnsonXarelto | $15 | $18,11916 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $142 | $17,89243 claims |
| Astellas Pharma US IncMyrbetriq | $2,947 | $11,12524 claims |
| AbbVieRestasis | $189 | $7,00416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,084 family medicine providers in New Jersey.
Other family medicine in Hawthorne
- Howard HassmanClementon$47.1M
- Matthew HongNorth Cape May$15.3M
- Rubaba HussainClark$3.8M
- Gaurang BrahmbhattHoboken$2.6M
- Michael DobrowClifton$2.1M
- Mikhail VarshavskiChatham$1.4M
- Amit BhalodiaCamden$707K
- Jennifer AmicoNew Brunswick$627K
- Janet ColeFar Hills$466K
- Matthew PintoMarlton$239K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.